Bicycle Therapeutics

Bicycle Therapeutics

Biotechnology Research

Cambridge, England 35,447 followers

Precision-Guided Therapeutics

About us

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.

Industry
Biotechnology Research
Company size
201-500 employees
Headquarters
Cambridge, England
Type
Public Company
Founded
2009
Specialties
Drug Discovery, Phage Display, Peptide Therapeutics, and Biotechnology

Locations

Employees at Bicycle Therapeutics

Updates

Similar pages

Browse jobs

Funding

Bicycle Therapeutics 14 total rounds

Last Round

Post IPO equity

US$ 555.0M

See more info on crunchbase